Mitotech
UK - LondonBiotechnology
Focus: Mitotech is a UK-based biotechnology company focused on small molecule therapeutics in ophthalmology, primarily targeting dry eye disease. The company operates at a pre-revenue or early-stage development phase with a focused pipeline in a specialized therapeutic area.
Profile data last refreshed Yesterday · AI intelligence enriched 2w ago
Open Jobs
0
About Mitotech
AI assessmentNot HiringNo open roles listed right now. Follow Mitotech to get notified when they start hiring — the background below is worth knowing for when they do.
Why Work Here
Data completeness
1/9 — Limited
Company HealthSolid
Pipeline
Mid-stage
2 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
Low Dose 0.155µg/mL SkQ1 ophthalmic solution
Keratoconjunctivitis SiccaClinical Trials (1)
NCT02121301A Clinical Study to Assess the Safety and Efficacy of an Ophthalmic Solution (SkQ1) in the Treatment of Dry Eye Syndrome (DES)
Phase 2Help build intelligence for Mitotech
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.